¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lymphocyte Culture Test, Mixed"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • sterile culture
    ¹«±Õ¹è¾ç
  • stick culture
    Âñ·¯½É±â, õÀÚ¹è¾ç
  • stock culture
    º¸Á¸¹è¾ç
  • streak plate culture
    Æì¹ß¶ó½É±â
  • suspension culture
    Çöʹè¾ç, ºÎÀ¯¹è¾ç
  • secondary culture
    ÀÌÂ÷¹è¾ç
  • shake culture
    Èçµé±â¹è¾ç
  • slant culture
    ºñÅ»¹èÁö½É±â, ºñÅ»¹èÁö¹è¾ç
  • slide cell culture
    ½½¶óÀ̵弼Æ÷¹è¾ç
  • slide culture
    ½½¶óÀ̵å¹è¾ç
  • vaginal smear culture
    Áúµµ¸»¹è¾ç, Áú¹Ù¸¥Ç¥º»¹è¾ç
  • watch glass culture
    ½Ã°èÁ¢½Ã¹è¾ç
  • acceptance test
    Àμö°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • needle culture
    (¢¡stab culture) Âñ·¯½É±â
  • organ culture
    Àå±â¹è¾ç
  • plate culture
    ÆòÆÇ¹è¾ç, ÆòÆÇ½É±â
  • pour culture
    ºÎ¾î½É±â
  • primary culture
    óÀ½½É±â
  • pure culture
    ¼ø¼ö¹è¾ç
  • quantitative culture
    Á¤·®¹è¾ç
  • roll culture
    ±¼¸®±â¹è¾ç
  • rollbottle culture
    º´±¼¸®±â¹è¾ç
  • rolltube culture
    ½ÃÇè°ü±¼¸®±â¹è¾ç
  • secondary culture
    µÎ¹øÂ°½É±â
  • shake culture
    Èçµé±â¹è¾ç
  • slant culture
    ºñÅ»¹èÁö½É±â
  • slide culture
    ½½¶óÀ̵å¹è¾ç
  • slide cell culture
    ½½¶óÀ̵弼Æ÷¹è¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Dick test
    µñÅ©½ÃÇè
  • Dick test
    µñ °Ë»ç
  • Donath-Landsteiner test
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê °Ë»ç
  • Draw-A-Person test(DAP)
    Àι°È­°Ë»ç
  • Du test
    Du °Ë»ç (ÁÖÀÇ : u ´Â À­Ã·ÀÚÀÓ)
  • Eleks gel-precipitin test
    ¿¤·ºÅ©ÇÑõÆòÆÇħ°­¹ý (µðÇÁÅ׸®¾Æµ¶¼Ò µ¿Á¤¹ý)
  • Falcon assay screening test
    ÆÈÄܺм®¼±º°½ÃÇè
  • Farnworth D-15 test
    ÆÄ¸¥¿ö½º15»ö»ó°Ë»ç
  • Farnworth-Munsell 100 hue test
    ÆÄ¸¥¿ö½º-¹®¼¿ 100»ö»ó°Ë»ç
  • Freda test
    ÇÁ·¹´Ù½ÃÇè
  • Frei s test
    ÇÁ¶óÀ̽ÃÇè<¹ÝÀÀ>
  • Frei test
    ÇÁ¶óÀ̽ÃÇè
  • Freis test
    ÇÁ¶óÀ̰˻ç
  • Friedman test
    ÇÁ¸®µå¸¸½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • mixed amputation
    È¥ÇÕ½Ä Àý´Ü(ûèùêãÒôîÓ¨).
  • mixed amputation
    È¥ÇÕ½ÄÀý´Ü(ûèùêãÒôîÓ¨).
  • mixed anesthesia
    È¥ÇÕ¸¶Ãë(¹ý)(¡­Ø«ö­Ûö).
  • mixed anxiety and depression
    È¥À缺 ºÒ¾È¿ì¿ïº´(ûèî¤àõ ÝÕäÌéØê¦Ü»)
  • mixed aphasia
    È¥ÇÕ¼º ½Ç¾îÁõ(¡­àõã÷åÞñø).
  • mixed aphasia
    È¥ÇÕ¼º ½Ç¾îÁõ(¡­àõã÷åÞñø).
  • mixed astigmatism
    È¥ÇÕ³­½Ã
  • mixed bacteria
    È¥ÇÕ¼¼±Õ
  • mixed base crude oil
    È¥ÇÕ±â¿øÀ¯(ûèùêÐñ ê«êú).
  • mixed beam irradiation
    È¥ÇÕºö¹æ»ç¼±Á¶»ç
  • mixed breech presentation
    º¹µÐÀ§ (ÜÙÔëêÈ).
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • mixed chancre
    È¥ÇÕ¼º Çϰ¨
  • mixed color
    È¥ÇÕ»ö(ûèùêßä).
  • mixed connective tissue disease
    È¥ÇÕ °áÇÕÁ¶Á÷º´
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • insulin stimulating test
    Àν¶¸° ÀڱؽÃÇè(í©Ð½ãËúÐ)
  • insulin tolerance test
    Àν¶¸° ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • interfacial test
    °è¸é°Ë»ç(Í£ØüËþÞÛ)
  • ketostix test
    ÄÉÅ佺ƽ°Ë»ç(ËþÞÛ)
  • lactose tolerance test
    "¶ôÅ佺 ºÎÇϰ˻ç(ݶùÃËþÞÛ), ¶ôÅ佺³»¼º°Ë»ç(Ò±àõËþÞÛ)"
  • liver function test
    °£±â´É °Ë»ç(ÊÜÐüÒöËþÞÛ)
  • load test
    ºÎÇϰ˻ç(ݶùÃËþÞÛ)
  • Luria-Delbrueck fluctuation test
    ·ç¸®¾Æ-µ¨ºê¸¯ ¿äµ¿½ÃÇè(èôÔÑãËúÐ)
  • metyrapone test
    ¸ÞƼ¶óÆù°Ë»ç(ËþÞÛ)
  • Molisch test
    ¸ô¸®½¬ ½ÃÇè(ãËúÐ)
  • Morner's test
    ¸ð³Ê ½ÃÇè(ãËúÐ)
  • murexide test
    ¹Â·¡½Ãµå°Ë»ç(ËþÞÛ)
  • patch test
    ÆÐÄ¡½ÃÇè(ãËúÐ)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phenolsulfonphthalein test
    Æä³î¼³ÆùÅ»·¹ÀÎ ½ÃÇè(ãËúÐ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
SRT sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r...
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
CTL cervico-thoraco-lumbar; control; cytolytic C lymphocyte; cytotoxic T-lymphocyte
HLA-LD human lymphocyte antigen-lymphocyte defined
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
FTOC Fetal Thymus Organ Culture
HTC Hepatoma Tissue Culture
hLTBMC human long-term bone marrow culture
LTC-IC Long-Term Culture Initiating Cells
LTBMC Long-term BM culture
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • air test
    °ø±â ½ÃÇè
  • alkali denaturation test
    ¾ËÄ®¸® º¯¼º ½ÃÇè
    žƼº Çì¸ð±Û·ÎºóÀÇ ³óµµ¸¦ ÃøÁ¤ÇÏ´Â ºÐ±¤ºñ»ö¹ýÀ¸·Î, °¨µµ´Â ÁßÁ¤µµÀÌ´Ù. ÀÌ ½ÃÇèÀº Çì¸ð±Û·Îºó ºÐÀÚ°¡ ¾ËÄ®¸®¿¡ ³ëÃâµÇ¾úÀ» ¶§ ±Û·Îºó ºÎºÐÀÇ º¯¼º¿¡ ´ëÇÑ Çì¸ð±Û·Îºó ºÐÀÚÀÇ ÀúÇ×µµ¿¡ ´Þ·Á ÀÖ´Ù.
  • Allen's test
    ¾Ë·» ½ÃÇè
  • allergen test
    ¾Ë·¹¸£°Õ ½ÃÇè
    ¾Ë·¹¸£±â¼º ÁúȯÀÇ ¿øÀÎÀÌ µÇ´Â ¾Ë·¹¸£°ÕÀ» °ËÃâ, È®ÀÎÇÏ´Â °Ë»ç¹ý. ½ÃÇè°ü³» ¹ÝÀÀ°ú »ýü ³» ¹ÝÀÀÀ¸·Î ³ª´¶´Ù. ½ÃÇè°ü³» ¹ÝÀÀ¿¡´Â Ç÷ûÇÐÀû ¹ÝÀÀ ¿Ü¿¡ ¹éÇ÷±¸ ¿ëü¹ÝÀÀÀ̳ª Ç÷¼ÒÆÇ ¿ëÇØ¹ÝÀÀ, È÷½ºÅ¸¹Î À¯¸®½ÃÇè, Å»°ú¸³ ½ÃÇè µîÀÌ ÀÖ´Ù. »ýü³» ¹ÝÀÀÀº, Á÷Á¢ ȯÀÚ¿¡°Ô ¾Ë·¹¸£°ÕÀ» Åõ¿©ÇÏ¿©, Áõ¼¼ÀÇ ¹ßÇöÀ» Á¶»çÇÏ´Â À¯¹ß½ÃÇè°ú, ´Ù¸¥ °Ç°­ÇÑ »ç¶÷¿¡°Ô ȯÀÚÀÇ Ç÷û, ¶Ç´Â ¹éÇ÷±¸¸¦ ÁÖ»çÇÑ ÈÄ ¾Ë·¹¸£°ÕÀ» Åõ¿©ÇÏ¿© ¹ÝÀÀÀ» º¸´Â Çǵ¿¼º Àü°¡½ÃÇèÀ¸·Î ³ª´¶´Ù. ÀüÀÚ¿¡´Â ÇǺΠ¹ÝÀÀÀ̳ª Á¡¸· ¹ÝÀÀÀÌ ÀÖ°í, ÈÄÀÚ¿¡´Â ÇÁ¶ó¿ì½º´ÏÃ÷-Äû½ºÆ®³Ê ¹ÝÀÀÀÌ ÀÖ´Ù.
  • alternate binaural loudness balance test
    ±³´ë¼º À½ Å©±â ÆòÇü ½ÃÇè, ¾çÀ̱³´ë À½ÆòÇü°Ë»ç, ¾çÀ̱³´ë¼º À½ÆòÇü °Ë»ç
  • alternate prism cover test
    ±³´ë ÇÁ¸®Áò °¡¸² °Ë»ç
  • Ames test
    ¿¡ÀÓ½º ½ÃÇè, ¿¡ÀÓ½º ½ÇÇè, µ¹¿¬º¯ÀÌ À¯¹ß ½ÃÇè
    1. ¿ÜÀμº È÷½ºÆ¼µòÀ» ÇÊ¿ä·Î ÇÏ´Â »ì¸ð³Ú¶ó ƼÇǹ¸®¿òÀÇ µ¹¿¬º¯ÀÌÁ¾À» ÀÌ¿ëÇÏ¿© È÷½ºÆ¼µòÀ» Á¦¿ÜÇÑ ¹èÁö¿¡ ½ÃÇèÇÒ È­Çй°ÁúÀ» ¿Ã·Á³õ¾Æ µ¹¿¬º¯ÀÌÁ¾ÀÌ Á¤»óÁ¾À¸·Î º¯È­½Ãų °¡´É¼ºÀÌ Å« °ÍÀ̹ǷΠ±×¸¸Å­ ¹ß¾Ï¼ºÀÌ Å©´Ù°í ÇÒ ¼ö ÀÖ´Ù. 2. ¹ß¾Ï¼º ¹°Áú ÃßÃâÀ» À§ÇÑ ½ÃÇèÀ¸·Î, È÷½ºÆ¼µò ÇÕ¼º¿¡ ÇÊ¿äÇÑ È¿¼Ò¸¦ °á¿©Çϰí ÀÖ´Â Salmonella ty
  • aminopyrine breath test
    ¾Æ¹Ì³ëÇǸ° È£Èí °Ë»ç
  • anesthetic test of pulp
    Ä¡¼ö ¸¶Ãë °Ë»ç
  • antiglobulin test
    Çױ۷κθ° °Ë»ç, Çױ۷κθ° ½ÃÇè
    ºÒ¿ÏÀü Ç×ü°¡ ÀûÇ÷±¸¿Í °áÇÕÇϸ鼭 ºñÀÀÁý¼ºÀÎ °æ¿ì, ŸÁ¾ µ¿¹°¿¡¼­ ÀÛ¼ºÇÑ Ç× IgG Ç×ü¸¦ Ãß°¡ÇÔÀ¸·Î½á ´Ù¸®°¡ ³õ¾ÆÁ® ÀÀÁý¹ÝÀÀÀÌ ¹ß»ýÇÑ´Ù. 1945³â Coombs¿¡ ÀÇÇÏ¿© Àç¹ß°ßµÈ ¹æ¹ýÀÌ¸ç »ýü ³»¿¡¼­ ÀÌ¹Ì ÀûÇ÷±¸¿Í °áÇÕÇϰí ÀÖ´Â Ç×ü¸¦ °ËÃâÇÏ´Â Á÷Á¢ ½ÃÇè°ú À¯¸®ÇØ ÀÖ´Â Ç×ü¸¦ ÀûÇ÷±¸¿Í °áÇÕ½ÃŰ°í ³ª¼­ °ËÃâÇÏ´Â °£Á¢ ½ÃÇèÀÌ ÀÖ´Ù.
  • apomorphine test
    ¾ÆÆ÷¸ð¸£ÇÉ ½ÃÇè
  • Apt test
    ¾ÐÆ® ½ÃÇè
  • arginine-insulin test
    ¾Æ¸£±â´Ñ-Àν¶¸° ½ÃÇè
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • Army General Classification test
    À°±º¼º ºÐ·ù ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
epitopes, t-lymphocyte Antigenic determinants recognised and bound by the T-cell receptor. Epitopes recognised by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
(12 Dec 1998)
tumour-infiltrating lymphocyte <haematology, oncology> Special cancer-fighting cells of the immune system found in tumours. In a type of experimental therapy, scientists harvest these cells from the tumour, grow them in a laboratory and then return them to the patient with the hope of the cells destroying the tumour.
These cells can be collected from the site of a tumour and exposed to IL-2 in vitro. When these cells are injected back into the tumour bearing host, they will specifically kill the tumour from which they originated.
(05 Mar 2000)
lymphocyte <haematology> White cell of the blood that are derived from stem cells of the lymphoid series.
Two main classes are recognised, T and B lymphocytes, the latter responsible (when activated) for production of antibody, the former subdivided into subsets (helper, suppressor, cytotoxic T-cells) and responsible both for cell-mediated immunity and for stimulating B-cells.
(18 Nov 1997)
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
lymphocyte cooperation T-cell enhancement of the B-cell response to thymic-dependent antigens.
(12 Dec 1998)
lymphocyte count A count of the number of lymphocytes in the blood.
(12 Dec 1998)
lymphocyte depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
(12 Dec 1998)
lymphocyte function associated antigen A member of the integrin family that is expressed on all leukocytes and binds to ICAM-1 and ICAM-2 on a variety of cells.
(05 Mar 2000)
lymphocyte function-associated antigen-1 A heterodimer molecule widely expressed on cells of haematopoietic origin. Cd11a antigen comprises the alpha chain and the CD18 antigen (antigens, CD18) the beta chain. Lfa-1 is a major receptor of T-cells, B-cells, and granulocytes. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by natural killer cells and granulocytes. Intracellular adhesion molecule-1 (icam-1) has been defined as a ligand for lfa-1.
(12 Dec 1998)
lymphocyte-oriented kinase <enzyme> An ste20-like protein kinase; genbank d89728
Registry number: EC 2.7.10.-
Synonym: lok gene product
(26 Jun 1999)
lymphocyte specific protein tyrosine kinase p56(lck) <enzyme> This enzyme is a lymphoid specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the il-2 receptor, and is thought to be involved in the earliest steps of tcr-mediated T-cell activation.
Registry number: EC 2.7.11.-
(12 Dec 1998)
lymphocyte subsets A classification of lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
lymphocyte transformation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
lymphocyte transfusion The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
(12 Dec 1998)
American Type Culture Collection <cell culture> A key resource for cultured cells, located in Rockville, USA.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • multiple choice test
    ¼±´ÙÇü Å×½ºÆ®
  • nuclear test
    ÇÙ½ÇÇè
  • nuclear test ban treaty
    ÇÙ½ÇÇè ±ÝÁö Á¶¾à
  • patch test
    øÆ÷ ½ÃÇè
  • paternity test
    ºÎ°è ½ÃÇè
  • performance test
    ÀÛ¾÷ °Ë»ç
  • personality test
    ¼º°Ý °Ë»ç
  • placement test
    (½ÅÀÔ»ý µûÀ§ÀÇ ¹ÝÆí¼ºÀ» À§ÇÑ)Çз Å×½ºÆ®
  • pop test
    =popquiz
  • pregnancy test
    ÀӽŠ°Ë»ç
  • projective test
    Åõ¿µ °Ë»ç¹ý(µµÇü µî¿¡ ÀÇÇÑ ¼º°Ý Å×½ºÆ®ÀÇ ÀÏÁ¾)
  • road test
    (»õÂ÷ÀÇ)³ë»ó ¼º´É ½ÃÇè;(¿îÀü¸éÇã ÃëµæÀ» À§ÇÑ)³ë»ó ½Ç±â ½ÃÇè;³ë»ó ¼º´É(½Ç±â)½ÃÇèÇÏ´Ù
  • scratch test
    ÇǺΠ¹ÝÀÀ ½ÃÇè
  • screen test
    ¿µÈ­ ¹è¿ìÀÇ Àû¼º(¹è¿ª) ½É»ç
  • skin test
    ÇǺΠ½ÃÇè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á